Champions Oncology vs Sutro Biopharma
CSBR and STRO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CSBR and STRO compare
Sutro Biopharma is the larger company, worth 2.6 times as much as Champions Oncology ($170M against $66.5M).
Champions Oncology grew revenue faster over the last twelve months (6.7% versus −56.3% for Sutro Biopharma).
Champions Oncology keeps more of each dollar of sales as profit, with a net margin of −1.8% compared with −395% at Sutro Biopharma.
Champions Oncology scores higher on the StockData Score (9 against 7 for Sutro Biopharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CSBR | STRO |
|---|---|---|
| Size and price | ||
| Market cap | $66.5M | $170M |
| Share price | $4.78 | $10.26 |
| Change, 1 year | −29.5% | 27.3% |
| Change, 5 years | −49.0% | −94.2% |
| Beta (5Y) | 0.36 | 2.21 |
| Employees | 214 | 137 |
| StockData Score | ||
| Total score | 9 (better) | 7 |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 | 1 |
| Performance score | 3 (better) | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.1× (better) | 3.7× |
| P/B | 17.1× | – |
| EV/EBITDA | 216× | – |
| FCF yield | −9.2% | – |
| Fair value | $1.36 | – |
| Margin of safety | −251% | – |
| Growth | ||
| Revenue growth (TTM) | 6.7% (better) | −56.3% |
| Revenue growth, 5Y average | 7.7% | 19.1% (better) |
| Net income growth (TTM) | −138% | – |
| EPS growth (TTM) | −140% | – |
| Profitability | ||
| Gross margin | 49.8% | – |
| Operating margin | −1.7% (better) | −320% |
| Net margin | −1.8% (better) | −395% |
| FCF margin | −10.1% | – |
| Return on equity | −29.8% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 1.03 | 3.32 (better) |
| Altman Z-score | −0.30 (better) | −8.74 |
| Piotroski F-score | 3 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 42.4% | 99.4% |
| Held by insiders | 30.5% | 6.1% |
| Insider net buying, 12 months | – | $0 |
| Short interest, % of float | 0.75% | 14.5% |
Go deeper
- CSBR stock overview
- CSBR income statement
- CSBR valuation and score
- STRO stock overview
- STRO income statement
- STRO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.